Premium
Opioids, cannabis, confidentiality, ethics, buprenorphine among highlights of 2019
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32582
Subject(s) - buprenorphine , confidentiality , cannabis , substance abuse , mental health , harm , looming , psychiatry , psychology , medicine , political science , opioid , law , social psychology , receptor , cognitive psychology
Opioids are still the dominant news story in the substance use disorder (SUD) field. Last year saw continued funding from the Substance Abuse and Mental Health Services Administration — and, of course, Congress — for the treatment field. Formulations of buprenorphine, the looming loss of confidentiality protections, the growing acceptance of cannabis, and a focus on quality and ethics were among the important stories for ADAW readers.